Address for correspondence: Professor David H. Barlow, Wolfson Medical School Building, University of Glasgow, University Avenue, Glasgow G12 8QQ, Scotland, UK. Voice: +44-141-330-3362. execdean{at}clinmed.gla.ac.uk
The evidence concerning the effects of hormone therapy (HT)
has been greatly expanded by the publication of very large randomized
controlled trials. A consequence has been concern among women
about the risks of HT such that the number of menopausal women
using HT for relief of menopausal symptoms has declined. It
is now appropriate to look at the best evidence available and
to consider current policies. Women in the early postmenopausal
phase, generally younger than 60 years of age, who are troubled
by menopausal symptoms should be reassured that, for their circumstances,
medical management of menopause in the form of HT is appropriate.
If they go on to use HT for several years, it is possible that
they will experience skeletal and coronary health benefits,
but the evidence for such benefits is a matter of ongoing debate.
